Reduction of carboplatin induced emesis by ondansetron.

[1]  L. Einhorn,et al.  Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Droz,et al.  Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. , 1990, The New England journal of medicine.

[3]  F. di Costanzo,et al.  Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Gandara,et al.  GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Schmoll.  The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. , 1989, European journal of cancer & clinical oncology.

[6]  M. Kris,et al.  Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Coombes,et al.  PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST , 1987, The Lancet.